Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 14, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On April 13, 2005, the GSK Trust transferred 13,222 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on April 14, 2005.
Outlook and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Consequently, three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold an interest in the shares held by the trust in the same manner as other employees.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust following the transfer of 13,222 shares.
- Confirm the specific allocation of the transferred shares among the SmithKline Beecham Employee Share Option Plan 1991 participants.
- Review the full list of directors' interests to ensure no other undisclosed changes occurred during this period.